Liminatus Pharma, Inc. Class A Common Stock
Price Action
Technical Summary
DOWNTRENDLiminatus Pharma, Inc. Class A Common Stock is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 3), showing significant lag compared to the market leaders. Earnings growth of 98% provides fundamental context to the price action. Investors should exercise caution due to high volatility (193% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.13 | -20.59% | BELOW |
| 50 SMA | $0.17 | -38.90% | BELOW |
| 100 SMA | $0.28 | -62.37% | BELOW |
| 150 SMA | $0.45 | -76.47% | BELOW |
| 200 SMA | $0.69 | -84.77% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LIMN in an uptrend right now?
LIMN has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.
Is LIMN overbought or oversold?
LIMN's RSI (14) is 30. The stock is in neutral territory, neither overbought nor oversold.
Is LIMN outperforming the market?
LIMN has a Relative Strength (RS) Rating of 3 out of 99. LIMN is currently lagging the broader market.
Where is LIMN in its 52-week range?
LIMN is trading at $0.11, which is 1% of its 52-week high ($12.90) and 0% above its 52-week low ($0.10).
How volatile is LIMN?
LIMN has a Beta of 0.28 and 52-week volatility of 193%. It's less volatile than the S&P 500 - generally more stable.